Even though the blood sugar levels are under control in patients of type 1 diabetes (T1D), they may experience "glycemic excursions", (blood sugar levels changing from high levels to low levels) with insulin.
A study shows a marked reduction in the blood sugar levels without the episodes of low blood sugar (glucose) levels (hypoglycemia) in most of the patients of type 1 diabetes (T1D) with dapagliflozin. Currently, dapagliflozin was being used for the treatment of type 2 diabetes (T2D).
Researchers have conducted a 24 week study (in 17 countries including the United States) named as the "Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes Study" (DEPICT-1), to find out the drug efficacy and safety as an adjunct treatment for insulin in patients of type 1 diabetes (T1D) with inadequately controlled blood glucose levels. The total number of participants in the first Phase 3 trial was 833, aged between 18 and 75 years.
The study shows that about 50 percent of the patients of type 1 diabetes (T1D) have successfully lowered their A1C levels by more than 0.5 percent without hypoglycemia (low blood sugar levels).
The authors say that the dapagliflozin is eligible for approval by the United States FDA as an antidiabetic agent for patients of type 1 diabetes (T1D) as the drug can lower HbA1c levels by about 0.5 percent. But they say that the drug needs further study to confirm the current study.
This study was funded by Bristol-Myers Squibb and AstraZeneca, the development partners of dapagliflozin. Manufacturers may likely to apply for the United States FDA approval after the 56-week DEPICT-1 study and DEPICT-2 study (a parallel study of dapagliflozin).
The senior author of the study was Professor Paresh Dandona, MD, Ph.D., chief of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo, United States.
A study at the Institute of Environmental Medicine (IMM), Karolinska Institutet, Sweden shows twice likely risk of diabetes, apart from the risk of high blood pressure (hypertension. BP) among people who consume more salt (as 40 percent of salt is sodium). The researchers say that the salt directly affects the insulin resistance.
The study shows 43 percent increased risk of type 2 diabetes (T2D) even with 2.5 grams of extra salt consumption (equal to one gram of sodium) per day. The study also shows 72 percent increased risk of type 2 diabetes (T2D) in individuals who consume more than 7.3 grams of salt per day when compared with individuals who consume less than six grams of salt per day.
The authors says that the people with human leukocyte antigen (HLA) and consuming high amounts of salt (more than 3.15 grams of salt per day) are at four times higher risk of type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) compared with people consuming low amounts of salt (less than 2.4 grams of salt per day).
The lead author of the study was Bahareh Rasouli, the Institute of Environmental Medicine (IMM). The study was presented at the annual meeting of the European Association for the Study of Diabetes (EASD) 2017, Lisbon, Portugal and published on September 14, 2017, in the Diabetologia. Title of the article was "Sodium (salt) intake is associated with a risk of developing type 2 diabetes."
Type 1.5 diabetes: Type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) is a type 1 diabetes (T1D) which appears during adulthood. The onset of LADA in adulthood is slower when compared to the onset of type 1 diabetes (T1D) in childhood. This occurs due to the destruction or damage to the insulin-producing beta cells in the pancreas.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.